Oracle today announced CancerMPact® Treatment Architecture Trends. The new cloud-based service enables pharmaceutical companies to analyze historical and global cancer treatment patterns to determine the impact of market events, such as new drug approvals, and the uptake of drugs and drug classes.

Treatment Architecture Trends is the latest module in CancerMPact, a comprehensive oncology decision support resource. It can be utilized for market sizing and analysis, strategic planning, and identification of commercial opportunities in the U.S., Europe, Japan, and China. The CancerMPact resource also includes the cloud-based integrated Future Trends and Insights, CancerLandscape, and Treatment Architecture modules.

“Understanding the opportunities and trends that exist within cancer treatments and standards of care is critical when designing pivotal development strategies for new therapies for cancer,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “Through our evolving CancerMPact platform, Oracle continues to help uncover new insights that drive critical decisions—as we have done for the largest pharmaceutical companies in the world for more than two decades.”

Treatment Architecture Trends assesses the current and historical trends in the clinical management of patients by site and stage for all cancer treatment modalities—including surgical, radiologic, and systemic agents, as well as untreated patient populations for up to 31 tumor types in the G8 markets. It provides users the ability to explore a rich data set of annual drug treatment (by stage, patient segment, and line of therapy), duration of therapy, modality use, and outcomes data that can help guide commercialization and treatment strategies.

Offered as an add-on to the existing Treatment Architecture module, the trends-focused service provides access to, and analysis of, more than seven years of cancer data (2017 to present) across four global geographies including the U.S., Japan, China, and the EU5 (Germany, Spain, France, Italy, and the United Kingdom). Oracle plans to continue to be expand the solution with new data being added in future years. The drug data can be queried and filtered by technology, target, and regimen within an interactive, cloud-based dashboard. The analysis can also be further segmented by physician specialty and treatment practice setting.

Additionally, drug approval events are provided for each geography to provide contextual understanding of impactful market events. As with all of the CancerMPact modules, users will also gain direct access to Oracle’s CancerMPact team for further support in exploring these rich longitudinal datasets derived from our physician survey-based Treatment Architecture reports.

Treatment Architecture and TA-Trends are based on Oracle’s proprietary online market research with direct responses from more than 7,500 oncology healthcare providers annually across the globe, representing more than 450,000 treated patients monthly. It offers added confidence due to the benefit of global consistency in our research methods, providing a more reliable comparison of treatment trends among the G8 countries, and curated standardization of historical data allows for appropriate year-over-year comparisons and analyses.

To learn more about CancerMPact, please visit: https://www.oracle.com/a/ocom/docs/industries/life-sciences/factsheet-cancermpact-improving-business-outcomes.pdf